European journal of ophthalmology · 2020
Topical corticosteroids in Acanthamoeba keratitis: Friend or foe?
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wouters Karlijn A, Verhoekx Jennifer Sn, van Rooij Jeroen, Wubbels René, van Goor Arnoud T
Аннотация
BACKGROUND/AIMS: To analyse the effect of topical corticosteroids before start of anti-amoebic therapy (AAT) in Acanthamoeba keratitis (AK) on final visual outcome and to identify factors that affect the outcome.
METHODS: A retrospective case control study of the medical records of patients diagnosed with AK at the Rotterdam Eye Hospital between 2003 and 2017 was performed. Patient demographic and clinical data were collected. The outcomes of patients treated with topical corticosteroids before the start of AAT were compared with those not treated with topical corticosteroids. Univariable and multivariable analyses were conducted.
RESULTS: A total of 109 patients was diagnosed with AK, with a mean follow-up time of 18 months. The use of corticosteroids was associated with a delay in diagnosis and thereby the start of AAT. In the non-steroids group, mean diagnostic delay was 23 days versus 62 days in the steroids group (p < 0.001). We found a statistically significant effect of pre-AAT steroid use on disease severity stage (p < 0.001). Also, a suboptimal visual outcome (⩽20/80) was seen significantly more frequent in the steroids group, as was the need for an urgent penetrating keratoplasty (PK) and for the total need of surgeries.
CONCLUSION: Use of corticosteroids before the start of AAT is associated with a suboptimal visual outcome, a significantly higher risk for a PK and a significantly more severe disease stage. It is important to continuously consider a differential diagnosis in a keratitis of unknown cause and to use corticosteroids cautiously before a definite diagnosis.
METHODS: A retrospective case control study of the medical records of patients diagnosed with AK at the Rotterdam Eye Hospital between 2003 and 2017 was performed. Patient demographic and clinical data were collected. The outcomes of patients treated with topical corticosteroids before the start of AAT were compared with those not treated with topical corticosteroids. Univariable and multivariable analyses were conducted.
RESULTS: A total of 109 patients was diagnosed with AK, with a mean follow-up time of 18 months. The use of corticosteroids was associated with a delay in diagnosis and thereby the start of AAT. In the non-steroids group, mean diagnostic delay was 23 days versus 62 days in the steroids group (p < 0.001). We found a statistically significant effect of pre-AAT steroid use on disease severity stage (p < 0.001). Also, a suboptimal visual outcome (⩽20/80) was seen significantly more frequent in the steroids group, as was the need for an urgent penetrating keratoplasty (PK) and for the total need of surgeries.
CONCLUSION: Use of corticosteroids before the start of AAT is associated with a suboptimal visual outcome, a significantly higher risk for a PK and a significantly more severe disease stage. It is important to continuously consider a differential diagnosis in a keratitis of unknown cause and to use corticosteroids cautiously before a definite diagnosis.